Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

The deal, announced in March and set to close in the second quarter, marks the Swiss pharmaceutical company’s latest bid to ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Vantive, a kidney care company that was spun off from Baxter International earlier this year, will establish its headquarters in Deerfield. Vantive, which formerly operated as Baxter’s Kidney ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Worthington Steel is moving its headquarters from its namesake city of Worthington to the Easton area after purchasing an office building there. On April 24, Worthington Steel acquired an office ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NYSE:NVO) has raised its annual sales guidance several times a year. But recent weak U.S ...